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Evidence That Tumor Necrosis Factor-Alpha–Induced Hyperinsulinemia
Prevents Decreases of Circulating Leptin During Fasting in Rats
Edward A. Medina, Kent L. Erickson, Kimber L. Stanhope, and Peter J. Havel
Administration of tumor necrosis factor-alpha (TNF-) acutely increases leptin gene expression and circulating leptin
concentrations in rodents and humans. Since TNF- also induces hyperinsulinemia, and because insulin is a potent stimulator
of leptin production, we hypothesized that elevated plasma insulin mediates TNF-–induced increases of circulating leptin.
To test this hypothesis, rats were made insulin-deficient with streptozotocin (STZ) and treated with subcutaneous implants
that released insulin at a constant rate and thereby “clamped” insulin levels. STZ-diabetic and nondiabetic rats were injected
with TNF- or vehicle; plasma leptin, insulin, and glucose concentrations were measured during an initial 12-hour postinjec-
tion period of fasting and after a subsequent 12-hour period of refeeding. Food intake during the 12 hours after fasting was
assessed as a physiologic correlate of changes in leptin concentrations. In nondiabetic rats, TNF- increased plasma insulin
(P  .016) and prevented the fasting-induced decrease of circulating leptin (P  .004) over the initial 12 hours compared with
vehicle. Food intake during the refeeding period was 30% lower (P  .008) when the nondiabetic animals were injected with
TNF-. In contrast, TNF- did not affect leptin concentrations in STZ-diabetic animals with clamped plasma insulin levels or
their food intake during the refeeding period. These results suggest that TNF-–induced hyperinsulinemia likely mediates the
stimulatory effect of TNF- on circulating leptin in vivo. Elevated leptin levels may in turn contribute to the effect of TNF-
to decrease food intake.
Copyright 2002, Elsevier Science (USA). All rights reserved.
ADMINISTRATION OF tumor necrosis factor- (TNF-)has been reported to acutely increase leptin gene expres-
sion and circulating leptin concentrations in rodents and hu-
mans.1-7 Whether TNF- increases circulating leptin levels by
directly stimulating leptin release from adipocytes is unclear.
While some studies have shown that TNF- stimulates leptin
secretion from cultured adipocytes,4-6,8 a number of others have
shown that the cytokine inhibits leptin release.8-12 However,
those studies that also examined the effects of TNF- on leptin
gene expression demonstrated that it inhibits leptin mRNA
levels.8-14 This contrasts with the increase in leptin mRNA that
is consistently observed after TNF- administration in ani-
mals.1,2,5-7 Thus, there is a discrepancy in the reported effects
of TNF- on leptin gene expression and secretion between
studies performed in vitro and those conducted with whole
animals.
Several studies have demonstrated that administration or
infusion of either endotoxin, TNF- or interleukin-1 (IL-1),
induces alterations in glucose homeostasis that include an ini-
tial period of hyperglycemia followed by increases of plasma
insulin and then a period of hypoglycemia.15-17 TNF- treat-
ment has also been shown to induce insulin resistance in
muscle, which would be expected to produce a compensatory
increase of insulin secretion and hyperinsulinemia, but it does
not appear to acutely affect insulin-mediated glucose uptake by
adipose tissue.18 Because insulin and adipocyte glucose metab-
olism are potent regulators of leptin production,19-26 we hy-
pothesized that the acute increase of plasma leptin following
TNF- administration in vivo results from a concomitant rise
of plasma insulin concentrations, which acts to increase leptin
production by adipose tissue.
To investigate whether TNF- acutely increases circulating
leptin levels by increasing plasma insulin concentrations, insu-
lin-deficient streptozotocin (STZ)-diabetic rats were treated
with subcutaneous implants that released a constant amount of
insulin, which “clamped” plasma insulin concentrations and
thereby prevented fluctuations of circulating insulin during the
experiment. Treatment with insulin also prevented the large
decrease of fat mass that accompanies STZ-induced insulin-
deficient diabetes.23,27 Plasma leptin in this insulin-treated di-
abetic rat model is responsive to supplemental insulin injec-
tions.23 STZ-diabetic and nondiabetic control animals were
then injected with TNF- or vehicle and blood samples col-
lected for measurement of plasma leptin, insulin, and glucose
during an initial 12-hour postinjection period of fasting, and
after a subsequent 12-hour period of refeeding. Based on the
hypothesis that TNF- stimulates the acute increase of leptin
via an increase of circulating insulin, we expected that TNF-
would not affect circulating leptin concentrations in the insulin-
clamped STZ-diabetic animals. In contrast, we expected that
fasting would decrease plasma leptin in untreated nondiabetic
animals,28-31 but that TNF- treatment would prevent this de-
crease by inducing an elevation of plasma insulin.
MATERIALS AND METHODS
Animals
Adult male Sprague-Dawley rats weighing 350 to 450 g (Charles
River, Wilmington, MA) were used for the studies. The animals were
individually housed in hanging wire cages in temperature-controlled
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rooms, and fed Purina chow (Ralston-Purina, St Louis, MO) and
deionized water ad libitum. The light/dark cycle was 12 hours on and
12 hours off, with lights on at 6 AM. The study protocol was approved
by the University of California, Davis Animal Care and Use Com-
mittee.
Induction of Diabetes and Insulin Implant Placement
Insulin-deficient diabetes was induced with subcutaneous injections
of freshly prepared STZ (Sigma, St Louis, MO) at a dose of 40 mg/kg
in ice-cold 0.5 mol/L citrate buffer (pH 4.5). A second dose of STZ (40
mg/kg) was administered 24 hours later. This regimen produces insu-
lin-deficient diabetes (plasma glucose 25 mmol/L) in more than 95%
of treated animals without inducing renal failure or losses from hypo-
glycemia.32 Nondiabetic animals received injections of citrate buffer
only. At the time of the second STZ injection, all of the STZ-diabetic
animals12 received 1.5 implants impregnated with bovine insulin (Lin-
plant, Toronto, Canada) placed subcutaneously through a 14-gauge
needle under ketamine-xylazine (30:10 mg/kg, respectively) anesthe-
sia. These implants slowly release insulin (2 U/d) for up to 40 days.
The nondiabetic rats were sham-implanted.
TNF- Response Study
Experiments were conducted 2 weeks following the induction of
diabetes. Tail blood samples were collected from both diabetic (n 12)
and nondiabetic (n  8) rats for baseline measurements at 8 AM of the
day prior to the experiment. On the day of the experiment, diabetic and
nondiabetic rats were randomly selected so that half of the animals in
each group would receive either TNF- or phosphate-buffered saline
(PBS). Then, 100 g/kg recombinant human TNF- (BioSource Inter-
national, Camarillo, CA) or the equivalent volume of PBS was injected
intraperitoneally. Blood samples were collected at 2 PM and 8 PM of the
same day and at 8 AM of the following day (ie, 6, 12, and 24-hour
postinjection). Because TNF- suppresses food intake33 and since
leptin concentrations are regulated by food intake,28-30 after injection,
the animals were fasted until 8 PM to control for treatment effects on
food intake. The animals were then allowed to eat ad libitum. Baseline
food intake was measured over the 24-hour period from 8 AM of the day
preceding to 8 AM of the day of the experiment. Food intake was also
assessed over the 12 -hour period after fasting between 8 PM of the day
of injection and 8 AM of the following day. After 1week, all of the
animals were “crossed-over” so rats that received a PBS injection the
first time received a TNF- injection the second time and vice versa.
Assays
Plasma leptin concentrations were measured in duplicate with a
specific radioimmunoassay for rat leptin (Linco Research, St Louis,
MO) as previously described.23 Plasma insulin concentrations were
measured in duplicate with a radioimmunoassay for rat insulin using rat
insulin standards (ICN Diagnostic Division, ICN, Costa Mesa, CA)
according to the method of Yalow and Berson with minor modifica-
tions34; the intra- and interassay variation are 7.0% and 9.0%, respec-
tively. Plasma glucose and lactate were measured with a glucose
analyzer (Yellow Springs Instruments, Yellow Springs, OH).
Data Analysis for TNF- Response Study
To compare treatment effects on plasma leptin, insulin, glucose, and
lactate concentrations between TNF- and PBS injection for diabetic
rats and between TNF- and PBS injection for nondiabetic rats, the
logarithm of the area under the curve (AUC) for these parameters (0 to
12 hours postinjection) was calculated for each animal to generate
summary measurements that were then analyzed by a paired t test
(2-tailed).35 If an overall significant effect of TNF- was found, indi-
vidual time points were analyzed with a paired t test for comparisons
within a treatment group (ie, baseline and postinjection responses). The
effects of TNF- at 24 hours postinjection were analyzed with a paired
t test (2-tailed). P values less than .05 were considered statistically
significant. Data are expressed as means  SEM.
RESULTS
Baseline Parameters
Prior to treatment with TNF- or PBS injection, the mean
baseline values for plasma leptin, insulin, glucose, and lactate
concentrations, food intake, and weight within the 2 experi-
mental groups (STZ-diabetic or nondiabetic) were not signifi-
cantly different from each other (Table 1). Similar to a recent
study we conducted with this insulin-treated, STZ-induced
diabetic rat model,27 insulin levels in the diabetic rats were
elevated compared with nondiabetic animals (P  .05). The
insulin implants normalized food intake and plasma lactate in
the diabetic animals, while leptin concentrations were slightly,
but not significantly, lower. Insulin treatment did not com-
pletely normalize plasma glucose concentrations (P  .05).
Prolonged insulin infusion can induce insulin resistance in
muscle but not adipose tissue.36 This likely explains why in-
sulin treatment was able to normalize plasma leptin but not
glucose. The inability to normalize glucose levels is also in-
dicative of the importance of hepatic insulin delivery to glucose
homeostasis; subcutaneously administered insulin does not
preferentially increase insulin concentrations within the hepatic
portal vein as when insulin is secreted from the pancreas.
Nonetheless, the purpose of the implants was to clamp insulin
concentrations and to prevent large decreases of fat mass in the
STZ-diabetic rats.
Table 1. Mean Baseline Plasma Leptin, Insulin, Glucose, and
Lactate Concentrations, Food Intake, and Weight, Prior
to TNF- or PBS Injection
PBS TNF-
Leptin (ng/mL)
Nondiabetic 7.0  1.1 7.0  0.8
Diabetic 5.9  1.0 4.6  1.0
Insulin (pmol/L)
Nondiabetic 145.8  32.4 159.6  34.2
Diabetic 553.2  61.2* 658.8  147.0*
Glucose (mmol/L)
Nondiabetic 8.1  0.2 8.0  0.2
Diabetic 12.8  1.8* 17.1  2.2*
Lactate (mmol/L)
Nondiabetic 2.6  0.2 2.7  0.2
Diabetic 2.7  0.1 3.2  0.3
Food intake (g/24 h)
Nondiabetic 31.5  1.0 31.2  1.3
Diabetic 32.3  1.2 31.9  1.7
Weight (g)
Nondiabetic 454.8  11.5 455.1  9.9
Diabetic 448.1  9.4 432.9  7.3
NOTE. Differences in mean baseline values prior to PBS or TNF-
injection, within the nondiabetic or diabetic group, and between
groups were tested by a paired and 2-sample t test, respectively.
Values are mean  SEM (n  8 diabetic rats; n  12 nondiabetic rats).
*P  .05 v nondiabetic animals.
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Plasma Leptin Concentrations
As expected, when vehicle (PBS) was administered to non-
diabetic rats, plasma leptin concentrations decreased markedly
from baseline levels during the 12-hour postinjection period of
fasting (  -4.1  0.7 ng/mL; P  .0012) (Fig 1A). In
contrast, when injected with TNF-, leptin levels did not de-
crease during the fast, and 12-hour postinjection concentrations
were not different from baseline levels (  -0.7  0.9
ng/mL). Over the entire 12-hour period, plasma leptin concen-
trations were higher following TNF- injection compared with
vehicle (P  .004); at 12 hours, mean leptin concentrations
were 2 times higher when the animals received TNF- com-
pared with PBS. After 12 hours of refeeding (ie, at 24 hours
postinjection), plasma leptin concentrations were restored to
baseline levels following PBS treatment and were not different
from those at that time point following TNF- treatment.
In contrast to nondiabetic animals, plasma leptin concentra-
tions did not decrease during fasting in diabetic rats in which
plasma insulin was clamped and were not affected by TNF-
administration over the 12-hour fasting period (P  .29; not
significant) or at the 24-hour time point (Fig 1B).
Plasma Insulin Concentrations
TNF- increased insulin concentrations in nondiabetic rats
over the 12-hour postinjection period compared with PBS (P
.016) (Fig 2A); at 6 hours, mean insulin levels were 1.7 times
greater than when the animals were injected with vehicle.
Insulin concentrations were maximally increased from baseline
levels at 6 hours ( 216.4% 87.5%; P .015) following
TNF- administration, whereas insulin levels did not change
after injection of PBS.
As expected, when insulin levels were clamped with slow-
release insulin implants in diabetic rats, TNF- administration
did not affect plasma insulin concentrations over the 12-hour
postinjection period (P  .71) (Fig 2B). There was a slight
tendency for insulin levels to increase over the 24-hour period
but the change was not significant.
Fig 2. Effect of TNF- injection on plasma insulin concentrations
in (A) nondiabetic and (B) diabetic rats. Animals were fasted for 12
hours following injection with 100 g/kg TNF- or PBS. Blood sam-
ples were collected at 6, 12, and 24 hours postinjection. Mean SEM;
n  8 nondiabetic and n  12 diabetic rats. *P < .05 v baseline.
Fig 1. Effect of TNF- injection on plasma leptin concentration in
(A) nondiabetic and (B) diabetic rats. Animals were fasted for 12
hours following injection with 100 g/kg TNF- or PBS. Blood sam-
ples were collected at 6, 12, and 24 hours postinjection.
Mean  SEM; n 8 nondiabetic and n  12 diabetic rats. *P < .005 v
baseline.
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Plasma Glucose Concentrations
Plasma glucose concentrations decreased modestly over the
12-hour postinjection period after TNF- administration in
nondiabetic rats (P  .01) (Fig 3A); at 6 and 12 hours, mean
plasma glucose concentrations were 82% and 88%, respec-
tively, of the glucose levels observed following injection with
vehicle. Glucose concentrations were maximally decreased
from baseline after TNF- administration at 6 hours ( 
-16.4%  4.3%; P  .006), whereas glucose levels did not
change after PBS administration.
Due to the continuous insulin release by the implants, plasma
glucose levels decreased markedly from baseline over the 12-
hour period of fasting in the diabetic animals; however, plasma
glucose concentrations in diabetic rats were not different be-
tween the TNF- and PBS treatments over the 12-hour postin-
jection period (P  .16) (Fig 3B). At 12 hours, glucose con-
centrations were similarly decreased from baseline following
TNF- or PBS injection by 76.9% 6.4% and 71.3% 5.1%,
respectively (P  .001 for both). Thus, although plasma glu-
cose was slightly, but not significantly, higher prior to TNF-
injection, the pattern of glucose changes was similar after
TNF- or vehicle injection. For both nondiabetic and diabetic
rats, plasma glucose concentrations at the 24-hour time point,
after the rats were allowed to refeed for 12 hours (Fig 3A and
B), were similar to baseline levels and not different between the
TNF- and PBS treatments.
Food Intake
As a result of insulin treatment the diabetic rats were not
hyperphagic and baseline food intake was similar for diabetic
and nondiabetic animals. During the 12-hour refeeding period
after the fasting period, food intake was decreased by approx-
imately 30% in the nondiabetic animals after TNF- adminis-
tration compared with when the animals received PBS (18.5 
1.8 v 26.1  0.6 g; P  .008) (Fig 4). In contrast, 12-hour food
intake during this period was not different between the TNF-
and PBS treatments in insulin-treated STZ-diabetic rats (25.3
2.0 v 27.6  1.1 g; P  .4).
DISCUSSION
When the proinflammatory cytokines TNF- or IL-1 are
administered to animals, they induce acute increases of circu-
lating leptin concentrations.1-7,37 Lipopolysaccharide (LPS)
also increases leptin levels, although TNF- and IL-1 likely
mediate that effect.4,38 In the present study, we demonstrated
that TNF- administration prevented leptin levels from de-
creasing during fasting in nondiabetic rats; leptin levels after 12
hours of fasting were nearly 2-fold greater when TNF- was
administered compared with when vehicle was injected. TNF-
also induced a nearly 2-fold increase of plasma insulin concen-
trations at 6 hours that preceded this difference in leptin levels.
In contrast, TNF- injection did not affect circulating leptin
concentrations in STZ-diabetic rats with subcutaneous insulin
implants that clamped plasma insulin concentrations. Thus,
increases of plasma insulin appear necessary in order for
TNF- to maintain leptin levels during fasting.
There are discrepancies in the reported effects of TNF- on
leptin gene expression and secretion between studies conducted
in vitro and those performed in vivo. The inhibitory effect of
Fig 4. Effect of TNF- injection on food intake in nondiabetic and
diabetic rats. Animals were fasted for 12 hours following injection
with 100 g/kg TNF- or PBS. Food intake was assessed for the 12 to
24 hours postinjection period. Mean  SEM; n  8 nondiabetic and n
 12 diabetic rats. *P < .005 v PBS.
Fig 3. Effect of TNF- injection on plasma glucose concentrations
in (A) nondiabetic and (B) diabetic rats. Animals were fasted for 12
hours following injection with 100 g/kg TNF- or PBS. Blood sam-
ples were collected at 6, 12, and 24 hours postinjection. Mean SEM;
n  8 nondiabetic and n  12 diabetic rats. *P < .005 v baseline.
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incubation with TNF- (24 hours) on leptin production was
demonstrated with cultured rat, mice and human adipocytes.8-13
One of those reports did demonstrate that a 4- to 8-hour
exposure to TNF- increased leptin release from human adi-
pocytes.8 A few other studies also demonstrated that TNF-
stimulates leptin release from adipocytes. One reported that
TNF- maximally stimulated leptin secretion from 3T3-L1
adipocytes at 6 hours by possibly regulating the release of
leptin from preformed pools,6 while another showed that an
8-hour exposure to TNF- stimulated leptin release from pri-
mary mouse adipocytes.4,5 However, several reports showed
that prolonged treatment (24 hours) of cultured adipocytes
with TNF- inhibited leptin mRNA levels.8-14 Leptin gene
expression was also decreased in 3T3-L1 or mouse brown
adipocytes after only a 4- to 6-hour treatment with TNF-.6,10
We have observed that an even shorter exposure (3 hours) to
TNF- did not affect leptin mRNA levels in 3T3-L1 adipo-
cytes, but it potently inhibited insulin-induced leptin mRNA
accumulation (unpublished observation, July 2001). Thus, re-
sults generated in vitro contrast with those from in vivo exper-
iments, which showed that leptin mRNA was increased in the
adipose tissue between 3 and 12 hours following TNF- ad-
ministration.1,2,5-7
Administration of TNF-, IL-1, or LPS to rodents stimulates
glycogenolysis and/or gluconeogenesis resulting in hypergly-
cemia followed by increases of circulating insulin concentra-
tions.16,39-42 This hyperinsulinemia then leads to enhanced glu-
cose utilization by particular tissues such as adipose tissue, and
hypoglycemia results when total glucose utilization, which also
includes non–insulin-mediated glucose uptake by macrophage-
rich tissues,42-44 excedes glucose production.45-47 Because in-
sulin-mediated glucose utilization is a potent stimulus for leptin
production by adipose tissue,24-26 it likely mediates the effect of
TNF-, IL-1, and LPS to increase circulating leptin in vivo.
Insulin’s role as a mediator is further supported by several
studies which showed that it acutely increases circulating leptin
and leptin mRNA levels in rodents,28,30,48,49 and directly stim-
ulates leptin release and gene expression in cultured adipo-
cytes.5,21,50 In the present study, TNF- clearly increased cir-
culating insulin concentrations in the nondiabetic rats.
Although not directly confirmed, this hyperinsulinemia proba-
bly increased insulin-mediated glucose utilization by adipose
tissue, which contributed to the observed decrease in plasma
glucose, and led to the stimulation of leptin production that
maintained plasma leptin during fasting. This mechanism is
supported by the inability of TNF- -injection to alter leptin in
diabetic rats in which plasma insulin levels were clamped.
An alternative interpretation for our results is that prolonged
exposure to supraphysiological insulin concentrations due to
the implants in the diabetic rats, may have somehow blunted
the stimulation of leptin production by TNF-. For example,
adipocytes isolated from rats chronically treated with insulin
were demonstrated to have decreased insulin responsiveness.51
If hyperinsulinemia indeed mediates TNF-’s stimulatory ef-
fect on leptin production, chronic insulin treatment could im-
pair the adipose tissue response to elevated plasma insulin in
rats. However, one group showed that prolonged insulin infu-
sion does not impair white adipose tissue insulin-mediated
glucose utilization in STZ-diabetic rats,52 and we have demon-
strated that plasma leptin in our insulin-treated diabetic rat
model is responsive to supplemental insulin injections.26 We
have also observed that glucocorticoid (dexamethasone) ad-
ministration can still acutely increase plasma leptin in these
animals (unpublished observation, April 2000). Thus, the adi-
pose tissue of chronic insulin-treated STZ-diabetic rats is re-
sponsive to other leptin secretagogues. We believe the most
likely explanation for the lack of effect of TNF- to increase
leptin secretion in the diabetic rats was that insulin levels were
clamped and could not increase after TNF- administration.
Based on the ability of TNF- and other proinflammatory
agents to decrease food intake and increase circulating leptin in
rodents, it was proposed that leptin mediates the anorexia and
weight-loss associated with infectious diseases and inflamma-
tion.2 However, TNF- modulates other factors that can regu-
late food intake, such as cholecystokinin (CCK), or it may
affect hypothalamic signaling molecules that act downstream
of leptin, such as -melanocyte–stimulating hormone (-MSH)
and neuropeptide Y (NPY).33 Thus, leptin’s role as a mediator
of TNF-’s effect on food intake is unclear. However, in the
present study, TNF- decreased the refeeding response in non-
diabetic rats, and at the time refeeding was initiated, plasma
leptin was 2 times higher compared with when they were
administered vehicle. Together with the observation that
TNF- did not affect food intake or leptin in diabetic rats, these
data suggest that leptin was a mediator of the TNF-–induced
decrease of food intake. This interpretation is supported by
numerous studies which demonstrated that leptin administra-
tion decreases food intake in rodents.31,53-55 In one related
study, intracerebroventricular leptin injections produced dose-
dependent decreases of food intake at 4 and 24 hours that were
comparable for STZ-diabetic and nondiabetic rats,54 indicating
that STZ-diabetic rats respond normally to the effects of leptin
to inhibit feeding.
In summary, TNF- prevented the decline of circulating
leptin concentrations during fasting in nondiabetic rats but had
no effect on leptin levels in STZ-diabetic rats with subcutane-
ous implants that clamped insulin levels. These results suggest
that TNF-–induced hyperinsulinemia mediates the effect of
TNF- to increase plasma leptin levels in vivo.
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